Effects of the route of oestrogen administration on IGF‐1 and IGFBP‐3 in healthy postmenopausal women: results from a randomized placebo‐controlled study
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Summary: Objective Oestrogens can modulate the action or secretion of GH. Previous studies in postmenopausal women have shown a differential effect between transdermal 17β‐oestradiol and oral ethynyl‐oestradiol on GH and IGF‐1 concentrations. This secondary analysis, based on a large randomized trial, aimed to estimate the effect of the route of administration of 17β‐oestradiol in combined hormone replacement therapy with progesterone on IGF‐1 and IGFBP‐3 levels. Design IGF‐1 and IGFBP‐3 were evaluated in a randomized study of 196 healthy postmenopausal women who were randomly allocated to receive on a continuous basis either 1 mg of 17β‐oestradiol orally combined with a daily intake of 100 mg progesterone (group 1; n = 63), or 50 µg of 17β‐oestradiol transdermally combined with a daily intake of 100 mg progesterone (group 2; n = 68), or triple dummy placebo (group 3; n = 65) over a 6‐month period. IGF1 and IGFBP‐3 levels were available for 133 women. Results Oral oestrogen significantly decreased IGF‐1 levels compared to placebo (P = 0·04) and transdermal oestrogen (P = 0·004), whereas transdermal oestrogen had no effect on IGF‐1 levels compared to placebo (P = 0·56). As regards IGFBP‐3, no significant difference was detected between the three groups. Conclusions Our data indicate that the route of oestrogen administration can influence IGF‐1 levels. IGF‐1 concentrations decreased significantly with oral oestrogen, whereas no significant change was observed with transdermal oestrogen at 6 months. The clinical relevance of these differential effects remains to be determined, particularly with regard to the risk for cardiovascular diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Premature mortality due to cardiovascular disease in hypopituitarism
Rosén, T., & Bengtsson, B.-Å. (1990) · The Lancet · doi:10.1016/0140-6736(90)91812-o · Cited by 1,402
Juul, A., Scheike, T., Davidsen, M., Gyllenborg, J., & Jørgensen, T. (2002) · Circulation · doi:10.1161/01.cir.0000027563.44593.cc · Cited by 640
WEISSBERGER, A. J., HO, K. K. Y., & LAZARUS, L. (1991) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-72-2-374 · Cited by 514
Laughlin, G. A., Barrett-Connor, E., Criqui, M. H., & Kritz-Silverstein, D. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030967 · Cited by 374
Vongpatanasin, W., Tuncel, M., Wang, Z., Arbique, D., Mehrad, B., & Jialal, I. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)00156-6 · Cited by 153
Estrogen replacement in women of fertile years with hypopituitarism
Mah, P. M., Webster, J., Jönsson, P., Feldt-Rasmussen, U., Koltowska-Häggström, M., & Ross, R. J. M. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1207 · Cited by 57
Cited by
Understanding weight gain at menopause
Davis, S. R., Castelo-Branco, C., Chedraui, P., Lumsden, M. A., Nappi, R. E., Shah, D., Villaseca, P., & as the Writing Group of the International Menopause Society for World Menopause Day 2012 (2012) · Climacteric · doi:10.3109/13697137.2012.707385 · Cited by 604
Smith, G. I., Yoshino, J., Reeds, D. N., Bradley, D., Burrows, R. E., Heisey, H. D., Moseley, A. C., & Mittendorfer, B. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2835 · Cited by 124
“Insulin, pM 22 (18, 30) 23 (19, 28) 19 (11, 29) 22 (15, 27) 28 (21, 39) 23 (19, 31) 22 (19, 25) 27 (19, 34)”
Effects of high dose oestrogen therapy on circulating inflammatory markers
Wilson, R., Spiers, A., Ewan, J., Johnson, P., Jenkins, C., & Carr, S. (2009) · Maturitas · doi:10.1016/j.maturitas.2009.01.009 · Cited by 59
Metadata
- Authors
- Sonnet, E., Lacut, K., Roudaut, N., Mottier, D., Kerlan, V., & Oger, E.
- Venue
- Clinical Endocrinology
- Publisher
- Wiley
- Published
- 2007-02-26
- Volume
- 66
- Issue
- 5
- Pages
- 626-631
- ISSN
- 0300-0664 (ISSN-L)
- 1365-2265
- OpenAlex
- W2060221405
- Cited by
- 44
- References
- 6
- FWCI
- 2.84
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.